highly significantP <0.0001
These results indicate that pre-epidemic baseline antibody cross reactivity was stronger in the elderly (≥60 yrs) and weaker in children and adolescents (<20 yrs) and adults (20–59 yrs), with highly significant differences between age groups ( P <0.0001).